Last reviewed 2026-04-20 · How we verify

DIGITALIS

Digitalis, a marketed drug, holds a significant position in its therapeutic category, though specific revenue figures are not provided. A key strength of Digitalis is its patent protection, which extends until 2028, providing a strong barrier to generic competition. The primary risk facing Digitalis is the eventual expiration of its key composition patent in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
• Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
• The Development of New Functions of Esculin and Digitalis Glycosides Eye Drops: A Study on the Treatment of Presbyopia (PHASE4)
• A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults (PHASE1)
• A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin (PHASE1)
• Digoxin Medulloblastoma Study (PHASE2)
• Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (PHASE3)
• Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.